Company / Revenue
Actinium Pharmaceuticals, Inc. Revenue History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$90.0K
FY2025
5-year range
$81.0K / $1.1M
FY2021-FY2025
Trend
+11.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue returned to growth in FY2025 after 2 years of decline, reaching $90,000.
Based on SEC 10-K filings.
$90,000 in FY2025 with a 3-year CAGR of -57.2%.
Declined from $1M to $90,000 over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- -57.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -57.2%, indicating a declining trend.
- In FY2025, revenue increased 11.1% year-over-year.
- Peak revenue was recorded in FY2022.
- Lowest revenue in the period was in FY2011.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $90.0K | +11.1% |
| FY2024 | $81.0K | -92.1% |
| FY2023 | $1.0M | -10.0% |
| FY2022 | $1.1M | +0.0% |
| FY2021 | $1.1M | - |
| FY2011 | $0 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026